Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure?

6 Jun 2024

Abstract excerpt

Recent trials show 5-year survival rates >95% for ETV6::RUNX1 Acute Lymphoblastic Leukemia (ALL). Since treatment has many side effects, an overview of cumulative drug doses and intensities between eight international trials is presented to characterize therapy needed for cure. A meta-analysis was performed as a comprehensive summary of survival outcomes at 5 and 10 years. For drug dose comparison in non-high...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research
Share to Childhood Cancer Survivors' Quality of Life

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38844578
DOI: 10.1038/s41375-024-02287-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure?PMID 38844578Read ↗

The Prognostic Effect of IKZF1 Deletions in ETV6::RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Genomic determinants of therapy response in ETV6::RUNX1 leukemia.Semantic proximity Read ↗

Toxicity profile and treatment delays in <scp>NOPHO ALL</scp>2008—comparing adults and children with Philadelphia chromosome‐negative acute lymphoblastic leukemiaSemantic proximity Read ↗

Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APLSemantic proximity Read ↗

Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trialSemantic proximity Read ↗

Copy number genome alterations are associated with treatment response and outcome in relapsed childhood ETV6/RUNX1-positive acute lymphoblastic leukemiaSemantic proximity Read ↗

Acute myeloid leukemia carrying ETV6 mutations: biologic and clinical features.Semantic proximity Read ↗

A tool compound targeting the core binding factor Runt domain to disrupt binding to CBFβ in leukemic cellsSemantic proximity Read ↗

Direct STAT3 and STAT5 Inhibition Overcomes Treatment Resistance in a Murine-Derived in vitro Model of Acute Lymphoblastic Leukaemia Driven by <italic>ETV6::JAK2</italic>.Semantic proximity Read ↗

The EphB6 receptor is overexpressed in pediatric T cell acute lymphoblastic leukemia and increases its sensitivity to doxorubicin treatmentSemantic proximity Read ↗

Anthracycline dose intensification in acute myeloid leukemia.Semantic proximity Read ↗

Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.